Kathryn Haviland
Chief Executive Officer en BLUEPRINT MEDICINES CORPORATION .
Fortuna: 15 M $ al 31/03/2024
Perfil
Kathryn Haviland forma parte del consejo de Fulcrum Therapeutics, Inc. y es directora de operaciones de Blueprint Medicines Corp., miembro de la Asociación de Antiguos Alumnos de la Industria de la Salud de la Escuela de Negocios de Harvard y miembro del Consejo Ejecutivo de Biopharma. Anteriormente, la Sra. Haviland ocupó el cargo de Vicepresidenta de Enfermedades Raras en Idera Pharmaceuticals, Inc., Jefa de Desarrollo Comercial en Sarepta Therapeutics, Inc. y Directora Ejecutiva de Desarrollo Comercial en PTC Therapeutics, Inc. Se licenció en la Universidad de Wesleyan y obtuvo un MBA en la Harvard Business School.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 07/03/2024 | 153 177 ( 0.25% ) | 15 M $ | 31/03/2024 | |
| 27/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Kathryn Haviland
| Empresas | Cargo | Inicio |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 04/04/2022 |
| FULCRUM THERAPEUTICS, INC. | Chairman | 10/01/2022 |
| Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16/10/2023 |
Antiguos cargos conocidos de Kathryn Haviland.
| Empresas | Cargo | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/12/2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2012 |
Formación de Kathryn Haviland.
| Wesleyan University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
| Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
- Bolsa de valores
- Insiders
- Kathryn Haviland
